Renalytix AI (GB:RENX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Renalytix AI, an AI-enabled diagnostics company focusing on kidney disease, has successfully raised £11.8 million through a stock placement and subscription at a premium price, with shares issued to Mount Sinai in exchange for debt forgiveness. CEO James McCullough expresses optimism for the company’s growth potential, expecting profitability and break-even cash flow in two years and forecasting revenues of approximately $17.5 million in FY27.
For further insights into GB:RENX stock, check out TipRanks’ Stock Analysis page.